İnsülin Alerjisi ve Desensitizasyonu
Özet
Alerji, bağışıklık sisteminin zararsız maddelere karşı gösterdiği aşırı duyarlılık reaksiyonudur. İnsülin preparatlarına karşı gelişen alerjik reaksiyonların insidansı %0.1 ile %7.1 arasında değişmektedir. 1980 sonrasında saflaştırılmış insülin üretim tekniklerinin yaygınlaşmasıyla bu sıklık belirgin şekilde azalmıştır. İnsülin alerjileri; IgE aracılı Tip 1 (erken reaksiyonlar) ile Tip 3 ve Tip 4 (geç reaksiyonlar) hipersensitivite reaksiyonları olarak sınıflandırılır. Erken reaksiyonlar enjeksiyondan sonraki ilk bir saat içinde kaşıntı, ürtiker veya hayatı tehdit eden anafilaksi şeklinde ortaya çıkabilir. Geç reaksiyonlar ise genellikle lokal endurasyon, hematom veya ekzamatöz cilt değişiklikleri ile karakterizedir. Alerjinin insülinin kendisine mi yoksa protamin, çinko, kresol gibi yardımcı maddelere mi karşı olduğunu belirlemek için deri prick, intradermal ve yama testleri uygulanır. Tedavide öncelikle antihistaminikler ve steroidler tercih edilirken, alternatif preparatlara geçiş veya kan şekeri kontrolünün zorunlu olduğu durumlarda subkutan/intravenöz insülin desensitizasyonu (duyarsızlaştırma) başarıyla uygulanabilmektedir. Dirençli vakalarda ise omalizumab veya immünsupresif tedaviler devreye girmektedir.
Allergy represents a hypersensitivity reaction of the immune system toward harmless substances. The incidence of allergic reactions to insulin preparations ranges between 0.1% and 7.1%. Following the 1980s, the widespread adoption of purified insulin production methods significantly decreased this frequency. Insulin allergies are classified into IgE-mediated Type 1 (early reactions) and Type 3 or Type 4 (late reactions) hypersensitivity. Early reactions may manifest within the first hour post-injection as pruritus, urticaria, or life-threatening anaphylaxis. Conversely, late reactions are characterized by local induration, hematoma, or eczematous skin lesions. Skin prick, intradermal, and patch tests are performed to determine whether the allergy is triggered by insulin itself or by excipients like protamine, zinc, or cresol. Although initial management relies on antihistamines and steroids, switching to alternative preparations or performing subcutaneous/intravenous insulin desensitization is highly effective when glycemic control is mandatory. For refractory cases, omalizumab or immunosuppressive agents are considered.
Referanslar
Fernandez L, Duque S, Montalban C, et al. Allergy to human insulin. Allergy. 2003;58(12):1317-1317. doi: 10.1046/j.1398-9995.2003.00324.x
Radermecker RP, Scheen A. Allergy reactions to insulin: effects of continuous subcutaneous insulin infusion and insulin analogues. Diabetes/Metabolism Research and Reviews. 2007;23(5):348-355. doi: 10.1002/dmrr.714
Ghazavi MK, Johnston GA. Insulin allergy. Clinics in Dermatology. 2011;29(3):300-305. doi: 10.1016/j.clindermatol.2010.11.009
Bliss M. The discovery of insulin. The Discovery of Insulin: University of Toronto Press; 2019. doi: 10.3138/9781442621480
Jersild M. INSULIN ZINC SUSPENSION: FOUR YEARS'EXPERIENCE. The Lancet. 1956;268(6951):1009-1013. doi: 10.1016/S0140-6736(56)90266-5
Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care. 1993;16(Supplement_3):155-165. doi: 10.2337/diacare.16.3.155
Katsoyannis PG, Tometsko A, Zalut C. Insulin Peptides. XII. Human Insulin Generation by Combination of Synthetic A and B Chains1. Journal of the American Chemical Society. 1966;88(1):166-167. doi: 10.1021/ja00953a033
Heinzerling L, Raile K, Rochlitz H, et al. Insulin allergy: clinical manifestations and management strategies. Allergy. 2008;63(2):148-155. doi: 10.1111/j.1398-9995.2007.01567.x
Sola-Gazagnes A, Pecquet C, Radermecker R, et al. Successful treatment of insulin allergy in a type 1 diabetic patient by means of constant subcutaneous pump infusion of insulin. Diabetes Care. 2003;26(10):2961-2962. doi: 10.2337/diacare.26.10.2961
Hasselmann C, Pecquet C, Bismuth E, et al. Continuous subcutaneous insulin infusion allows tolerance induction and diabetes treatment in a type 1 diabetic child with insulin allergy. Diabetes & Metabolism. 2013;39(2):174-177. doi: 10.1016/j.diabet.2012.10.002
Pichler WJ. Drug hypersensitivity reactions: classification and relationship to T-cell activation. Drug Hypersensitivity: Karger Publishers; 2007:168-189. doi: 10.1159/000104199
Kawanami D, Ito T, Watanabe Y, et al. Successful control of a case of severe insulin allergy with liraglutide. Journal of Diabetes Investigation. 2013;4(1):94-96. doi: 10.1111/j.2040-1124.2012.00239.x
Chng H, Leong K, Loh K. Primary systemic allergy to human insulin: recurrence of generalized urticaria after successful desensitization. Allergy. 1995;50(12):984-987. doi: 10.1111/j.1398-9995.1995.tb02512.x
Grammer L. Insulin allergy. Clinical reviews in allergy. 1986;4(2):189-200. doi: 10.1007/BF02991108
Alvarez-Thull L, Rosenwasser LJ, Brodie TD. Systemic allergy to endogenous insulin during therapy with recombinant DNA (rDNA) insulin. Annals of Allergy, Asthma & Immunology. 1996;76(3):253-256. doi: 10.1016/S1081-1206(10)63436-9
Brange J, Andersen L, Laursen ED, et al. Toward understanding insulin fibrillation. Journal of pharmaceutical Sciences. 1997;86(5):517-525. doi: 10.1021/js960297s
Maislos M, Mead P, Gaynor D, Robbins D. The source of the circulating aggregate of insulin in type I diabetic patients is therapeutic insulin. The Journal of Clinical İnvestigation. 1986;77(3):717-723. doi: 10.1172/JCI112366
Velcovsky H, Federlin K. Insulin-specific IgG and IgE antibody response in type I diabetic subjects exclusively treated with human insulin (recombinant DNA). Diabetes Care. 1982;5(Supplement_2):126-128. doi: 10.2337/diacare.5.2.S126
Darmon P, Castera V, Koeppel M-C, et al. Type III allergy to insulin detemir. Diabetes Care. 2005;28(12):2980-2980. doi: 10.2337/diacare.28.12.2980-a
Heinzerling L, Adkinson N, Nathan D, et al. Hypersensitivity reactions to insulins. (23/04/2022 tarihinde https://www.uptodate.com/contents/hypersensitivity-reactions-to-insulins?search=insulin%20allergy&source=search_result&selectedTitle=1~8&usage_type=default&display_rank=1 adresinden erişilmiştir. )
Goldfine A, Kahn C. Insulin allergy and insulin resistance. Current therapy in endocrinology and Metabolism. 1994;5:461-464. doi: : 10.1080/00325481.1978.11714725
Bodtger U, Wittrup M. A rational clinical approach to suspected insulin allergy: status after five years and 22 cases. Diabetic Medicine. 2005;22(1):102-106. doi: 10.1111/j.1464-5491.2004.01352.x
Wheeler BJ, Taylor BJ. Successful management of allergy to the insulin excipient metacresol in a child with type 1 diabetes: a case report. Journal of Medical Case Reports. 2012;6(1):1-4. doi:10.1186/1752-1947-6-263
Takata H, Kumon Y, Osaki F, et al. The human insulin analogue aspart is not the almighty solution for insulin allergy. Diabetes Care. 2003;26(1):253-254. doi: 10.2337/diacare.26.1.253
Matheu V, Perez E, Hernández M, et al. Insulin allergy and resistance successfully treated by desensitisation with Aspart insulin. Clinical and Molecular Allergy. 2005;3(1):1-5. doi:10.1186/1476-7961-3-16
Atik D, Büyükcam F, Yılmaz D, et al. Angioedema after the first dose of metformin. The American Journal of Emergency Medicine. 2013;31(3):634. e635. doi: 10.1016/j.ajem.2012.10.021
Pérez E, Martínez-Tadeo J, Callero A, et al. A case report of allergy to exenatide. The Journal of Allergy and Clinical immunology. In Practice. 2014;2(6):822-823. doi: 10.1016/j.jaip.2014.05.011
Moyes V, Driver R, Croom A, et al. Insulin allergy in a patient with type 2 diabetes successfully treated with continuous subcutaneous insulin infusion. Diabetic Medicine. 2006;23(2):204-206. doi: 10.1111/j.1464-5491.2006.01811.x
Näf S, Esmatjes E, Recasens M, et al. Continuous subcutaneous insulin infusion to resolve an allergy to human insulin. Diabetes Care. 2002;25(3):634-635. doi: 10.2337/diacare.25.3.634-a
Asai M, Yoshida M, Miura Y. Immunologic tolerance to intravenously injected insulin. New England Journal of Medicine. 2006;354(3):307-309. doi: 10.1056/NEJMc052463
Andrade P, Barros L, Gonçalo M. Type 1 Ig-E mediated allergy to human insulin, insulin analogues and beta-lactam antibiotics. Anais Brasileiros de Dermatologia. 2012;87:917-919. doi: 10.1590/S0365-05962012000600018
Chu Y-Q, Cai L-J, Jiang D-C, Jia D, et al. Allergic shock and death associated with protamine administration in a diabetic patient. Clinical Therapeutics. 2010;32(10):1729-1732. doi: 10.1016/j.clinthera.2010.09.010
Stewart WJ, McSweeney SM, Kellett MA, et al. Increased risk of severe protamine reactions in NPH insulin-dependent diabetics undergoing cardiac catheterization. Circulation. 1984;70(5):788-792. doi: 10.1161/01.CIR.70.5.788
Weiss ME, Adkinson NF. Allergy to protamine. Clinical Reviews in Allergy. 1991;9(3):339-355. doi: 10.1007/BF02802312
Weiss M, Chatham F, Kagey-Sobotka A, et al. Serial immunological investigations in a patient who had a life‐threatening reaction to intravenous protamine. Clinical & Experimental Allergy. 1990;20(6):713-720. doi: 10.1111/j.1365-2222.1990.tb02713.x
Porsche R, Brenner ZR. Allergy to protamine sulfate. Heart & Lung. 1999;28(6):418-428. doi: 10.1016/S0147-9563(99)70031-2
Chang L-C, Liang JF, Lee H-F, et al. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): in vitro evaluation of efficacy and toxicity. Aaps Pharmsci. 2001;3(3):15-23. doi: 10.1208/ps030318
Roest M, Shaw S, Orton D. Insulin-injection-site reactions associated with type I latex allergy. New England Journal of Medicine. 2003;348(3):265-266. doi: 10.1056/NEJM200301163480320
Heinzerling L, Mari A, Bergmann K-C, et al. The skin prick test–European standards. Clinical and Translational Allergy. 2013;3(1):1-10. doi:10.1186/2045-7022-3-3
Lee A-Y, Chey W-Y, Choi J, et al. Insulin-induced drug eruptions and reliability of skin tests. Acta Dermato-Venereologica. 2002;82(2):114-117. doi: 10.1080/00015550252948149
DeShazo RD, Mather P, Grant W, et al. Evaluation of patients with local reactions to insulin with skin tests and in vitro techniques. Diabetes Care. 1987;10(3):330-336. doi: 10.2337/diacare.10.3.330
Madero M, Sastre J, Carnes J, et al. IgG4‐mediated allergic reaction to glargine insulin. Allergy. 2006;61(8):1022-1023. doi: 10.1111/j.1398-9995.2006.01117.x
Yuan T, Zhao W, Wang L, et al. Continuous subcutaneous insulin infusion as an effective method of desensitization therapy for diabetic patients with insulin allergy: a 4-year single-center experience. Clinical Therapeutics. 2016;38(11):2489-2494. doi: 10.1016/j.clinthera.2016.09.018
Wu P, Ji C, Wang M, et al. Desensitization of allergy to human insulin and its analogs by administering insulin aspart and insulin glargine. Paper presented at: Annales d'endocrinologie, 2013. doi: 10.1016/j.ando.2012.11.005
Yokoyama H, Fukumoto S, Koyama H, et al. Insulin allergy; desensitization with crystalline zinc-insulin and steroid tapering. Diabetes Research and Clinical Practice. 2003;61(3):161-166. doi: 10.1016/S0168-8227(03)00114-1
Eguíluz-Gracia I, Rodríguez-Álvarez M, Cimarra-Álvarez M, et al. Desensitization for insulin allergy: a useful treatment also for local forms. Journal of Investigational Allergology & Clinical Immunology. 2012;22(3):215-216.
Jutel M, Akdis M, Budak F, et al. IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. European journal of immunology. 2003;33(5):1205-1214. doi: 10.1002/eji.200322919
Mattson JR, Patterson R, Roberts M. Insulin therapy in patients with systemic insulin allergy. Archives of internal medicine. 1975;135(6):818-821. doi: 10.1001/archinte.1975.00330060062008
Fujikawa T, Imbe H, Date M, et al. Severe insulin allergy successfully treated with continuous subcutaneous insulin infusion. Diabetes Research and Clinical Practice. 2012;97(2):e31-e33. doi: 10.1016/j.diabres.2012.04.027
Rojas J, Villalobos M, Martínez MS, et al. Successful management of insulin allergy and autoimmune polyendocrine syndrome type 4 with desensitization therapy and glucocorticoid treatment: a case report and review of the literature. Case Reports in Immunology. 2014;2014. doi: 10.1155/2014/394754
Jacquier J, Chik C, Senior P. A practical, clinical approach to the assessment and management of suspected insulin allergy. Diabetic Medicine. 2013;30(8):977-985. doi: 10.1111/dme.12194
Frigerio C, Aubry M, Gomez F, et al. Desensitization‐resistant insulin allergy. Allergy. 1997;52(2):238-239. doi: 10.1111/j.1398-9995.1997.tb00988.x
Witters LA, Ohman JL, Weir GC, et al. Insulin antibodies in the pathogenesis of insulin allergy and resistance. The American Journal of Medicine. 1977;63(5):703-709. doi: 10.1016/0002-9343(77)90155-3
Cavelti-Weder C, Muggli B, Keller C, et al. Successful use of omalizumab in an inadequately controlled type 2 diabetic patient with severe insulin allergy. Diabetes Care. 2012;35(6):e41-e41. doi: 10.2337/dc12-0115
Yong PF, Malik R, Arif S, et al. Rituximab and omalizumab in severe, refractory insulin allergy. New England Journal of Medicine. 2009;360(10):1045-1047. doi: 10.1056/NEJMc0808282
Mandrup-Poulsen T, Mølvig J, Pildal J, et al. Leukocytoclastic vasculitis induced by subcutaneous injection of human insulin in a patient with type 1 diabetes and essential thrombocytemia. Diabetes Care. 2002;25(1):242-243. doi: 10.2337/diacare.25.1.242
Silva ME, Mendes MJ, Ursich MJ, et al. Human insulin allergy-immediate and late type III reactions in a long-standing IDDM patient. Diabetes Research and Clinical Practice. 1997;36(2):67-70. doi: 10.1016/S0168-8227(97)00031-4
Clerx V, Van Den Keybus C, Kochuyt A, et al. Drug intolerance reaction to insulin therapy caused by metacresol. Contact Dermatitis. 2003;48(3):162-163. doi: 10.1034/j.1600-0536.2003.00034.x
